O'Connor D T, Preston R A, Mitas J A, Frigon R P, Stone R A
Hypertension. 1981 Jan-Feb;3(1):139-47. doi: 10.1161/01.hyp.3.1.139.
To evaluate the mechanism of chronic thiazide diuretic action in hypertension, we treated 19 essential hypertensive white men for 1-month periods on placebo alone and hydrochlorothiazide alone. During therapy, mean arterial pressure (MAP) fell, but radioisotopically determined intravascular volume remained unchanged, suggesting other mechanisms of thiazide action upon blood pressure. In the renal circulation, thiazides did not change renal plasma flow or glomerular filtration rate, but renovascular resistance was diminished, probably at the afferent arteriole. Concomitant with the decline in blood pressure and renovascular resistance, urinary kallikrein excretion increased, from subnormal (hypertensive) levels back into the normal range. The kallikrein increase did not correlate with changes in plasma aldosterone. In addition, patients with blood pressure responses (reduction greater than or equal to 10%) to thiazides (n = 12) had greater increases in kallikrein excretion than those without such a blood pressure decrement (n = 7), suggesting a role for renal kallikrein in the hypotensive response to thiazide diuretics.
为评估慢性噻嗪类利尿剂在高血压治疗中的作用机制,我们对19名原发性高血压白人男性进行了为期1个月的治疗,分别单独使用安慰剂和单独使用氢氯噻嗪。治疗期间,平均动脉压(MAP)下降,但放射性同位素测定的血管内容量保持不变,提示噻嗪类药物对血压的作用存在其他机制。在肾循环中,噻嗪类药物并未改变肾血浆流量或肾小球滤过率,但肾血管阻力降低,可能是在入球小动脉处。随着血压和肾血管阻力的下降,尿激肽释放酶排泄增加,从低于正常(高血压)水平回升至正常范围。激肽释放酶的增加与血浆醛固酮的变化无关。此外,对噻嗪类药物有血压反应(血压降低大于或等于10%)的患者(n = 12)激肽释放酶排泄的增加幅度大于无血压下降的患者(n = 7),提示肾激肽释放酶在噻嗪类利尿剂的降压反应中起作用。